233 related articles for article (PubMed ID: 25904021)
1. Nsc23925 prevents the development of paclitaxel resistance by inhibiting the introduction of P-glycoprotein and enhancing apoptosis.
Yang X; Shen J; Gao Y; Feng Y; Guan Y; Zhang Z; Mankin H; Hornicek FJ; Duan Z
Int J Cancer; 2015 Oct; 137(8):2029-39. PubMed ID: 25904021
[TBL] [Abstract][Full Text] [Related]
2. NSC23925 prevents the emergence of multidrug resistance in ovarian cancer in vitro and in vivo.
Yang X; Feng Y; Gao Y; Shen J; Choy E; Cote G; Harmon D; Zhang Z; Mankin H; Hornicek FJ; Duan Z
Gynecol Oncol; 2015 Apr; 137(1):134-42. PubMed ID: 25677062
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and evaluation of (2-(4-methoxyphenyl)-4-quinolinyl)(2-piperidinyl)methanol (NSC23925) isomers to reverse multidrug resistance in cancer.
Duan Z; Li X; Huang H; Yuan W; Zheng SL; Liu X; Zhang Z; Choy E; Harmon D; Mankin H; Hornicek F
J Med Chem; 2012 Apr; 55(7):3113-21. PubMed ID: 22400811
[TBL] [Abstract][Full Text] [Related]
4. Prevention of multidrug resistance (MDR) in osteosarcoma by NSC23925.
Yang X; Yang P; Shen J; Osaka E; Choy E; Cote G; Harmon D; Zhang Z; Mankin H; Hornicek FJ; Duan Z
Br J Cancer; 2014 Jun; 110(12):2896-904. PubMed ID: 24853187
[TBL] [Abstract][Full Text] [Related]
5. NSC23925, identified in a high-throughput cell-based screen, reverses multidrug resistance.
Duan Z; Choy E; Hornicek FJ
PLoS One; 2009 Oct; 4(10):e7415. PubMed ID: 19823672
[TBL] [Abstract][Full Text] [Related]
6. Antivascular therapy for orthotopic human ovarian carcinoma through blockade of the vascular endothelial growth factor and epidermal growth factor receptors.
Thaker PH; Yazici S; Nilsson MB; Yokoi K; Tsan RZ; He J; Kim SJ; Fidler IJ; Sood AK
Clin Cancer Res; 2005 Jul; 11(13):4923-33. PubMed ID: 16000591
[TBL] [Abstract][Full Text] [Related]
7. Modulation of drug resistance in ovarian adenocarcinoma by enhancing intracellular ceramide using tamoxifen-loaded biodegradable polymeric nanoparticles.
Devalapally H; Duan Z; Seiden MV; Amiji MM
Clin Cancer Res; 2008 May; 14(10):3193-203. PubMed ID: 18483388
[TBL] [Abstract][Full Text] [Related]
8. Reversal of multidrug resistance by two nordihydroguaiaretic acid derivatives, M4N and maltose-M3N, and their use in combination with doxorubicin or paclitaxel.
Chang CC; Liang YC; Klutz A; Hsu CI; Lin CF; Mold DE; Chou TC; Lee YC; Huang RC
Cancer Chemother Pharmacol; 2006 Nov; 58(5):640-53. PubMed ID: 16544145
[TBL] [Abstract][Full Text] [Related]
9. Cisplatin inhibits paclitaxel-induced apoptosis in cisplatin-resistant ovarian cancer cell lines: possible explanation for failure of combination therapy.
Judson PL; Watson JM; Gehrig PA; Fowler WC; Haskill JS
Cancer Res; 1999 May; 59(10):2425-32. PubMed ID: 10344753
[TBL] [Abstract][Full Text] [Related]
10. Combining the farnesyltransferase inhibitor lonafarnib with paclitaxel results in enhanced growth inhibitory effects on human ovarian cancer models in vitro and in vivo.
Taylor SA; Marrinan CH; Liu G; Nale L; Bishop WR; Kirschmeier P; Liu M; Long BJ
Gynecol Oncol; 2008 Apr; 109(1):97-106. PubMed ID: 18237771
[TBL] [Abstract][Full Text] [Related]
11. Folic acid-coupled nano-paclitaxel liposome reverses drug resistance in SKOV3/TAX ovarian cancer cells.
Tong L; Chen W; Wu J; Li H
Anticancer Drugs; 2014 Mar; 25(3):244-54. PubMed ID: 24275314
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of phosphatidylinositol 3'-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models.
Hu L; Hofmann J; Lu Y; Mills GB; Jaffe RB
Cancer Res; 2002 Feb; 62(4):1087-92. PubMed ID: 11861387
[TBL] [Abstract][Full Text] [Related]
13. Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells.
Cuello M; Ettenberg SA; Nau MM; Lipkowitz S
Gynecol Oncol; 2001 Jun; 81(3):380-90. PubMed ID: 11371126
[TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo characterizations of tetrandrine on the reversal of P-glycoprotein-mediated drug resistance to paclitaxel.
Zhu X; Sui M; Fan W
Anticancer Res; 2005; 25(3B):1953-62. PubMed ID: 16158930
[TBL] [Abstract][Full Text] [Related]
15. In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576.
Mistry P; Stewart AJ; Dangerfield W; Okiji S; Liddle C; Bootle D; Plumb JA; Templeton D; Charlton P
Cancer Res; 2001 Jan; 61(2):749-58. PubMed ID: 11212278
[TBL] [Abstract][Full Text] [Related]
16. In vitro and in vivo histone deacetylase inhibitor therapy with suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer.
Cooper AL; Greenberg VL; Lancaster PS; van Nagell JR; Zimmer SG; Modesitt SC
Gynecol Oncol; 2007 Mar; 104(3):596-601. PubMed ID: 17049973
[TBL] [Abstract][Full Text] [Related]
17. Emodin sensitizes paclitaxel-resistant human ovarian cancer cells to paclitaxel-induced apoptosis in vitro.
Li J; Liu P; Mao H; Wanga A; Zhang X
Oncol Rep; 2009 Jun; 21(6):1605-10. PubMed ID: 19424643
[TBL] [Abstract][Full Text] [Related]
18. Combination therapy of zibotentan with cisplatinum and paclitaxel is an effective regimen for epithelial ovarian cancer.
RosanĂ² L; Cianfrocca R; Spinella F; Di Castro V; Natali PG; Bagnato A
Can J Physiol Pharmacol; 2010 Jun; 88(6):676-81. PubMed ID: 20628434
[TBL] [Abstract][Full Text] [Related]
19. In vitro and in vivo histone deacetylase inhibitor therapy with vorinostat and paclitaxel in ovarian cancer models: does timing matter?
Modesitt SC; Parsons SJ
Gynecol Oncol; 2010 Nov; 119(2):351-7. PubMed ID: 20673975
[TBL] [Abstract][Full Text] [Related]
20. Receptor tyrosine kinase (RTK) inhibition is effective in chemosensitising EGFR-expressing drug resistant human ovarian cancer cell lines when used in combination with cytotoxic agents.
Coley HM; Shotton CF; Ajose-Adeogun A; Modjtahedi H; Thomas H
Biochem Pharmacol; 2006 Oct; 72(8):941-8. PubMed ID: 16934227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]